Login to Your Account



Suzhou Connect starts phase I trials for S1P1 modulator in Australia

By Shannon Ellis
Staff Writer

Tuesday, November 18, 2014
SHANGHAI – For a small start-up with only two and a half years under its belt, Suzhou Connect Biopharmaceuticals Inc., of Suzhou, Jiangsu, is understandably pleased to be kicking off its phase I trials for CBP-307 in Australia.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription